Updates on FDA Recalls of Valsartan
Breit Cantor Grana Buckner—February 21, 2019
If you are taking valsartan or another angiotensin II receptor blocker (ARB), you have likely heard about the recent recalls and investigations being reported and conducted by the U.S. Food and Drug Administration (FDA). Related recalls continue to pile up and many similar products are being investigated for the presence of dangerous substances such as NDMA and unsafely high levels of other ingredients.
Aurobindo Voluntarily Recalls Valsartan Tablets Due to NDEA
Aurobindo Pharma USA has recalled two batches of valsartan tablets, including multiple lots that contain a combination of valsartan and either HCTZ or amlodipine. The recall is being conducted due to an unsafe amount of N-Nitrosodiethylamine (NDEA), which has been found to be above the acceptable daily intake of 0.083 ppm in the recalled batches.
Medications that only contain amlodipine or HCTZ are not part of the recall. Only those containing HCTZ or amlodipine and valsartan or losartan are being recalled.
Click here for updated information about voluntary and FDA-mandated recalls of valsartan and another angiotensin II receptor-blocking (ARB) medications.
Have You Been Harmed by Taking Valsartan? Call (855) 212-8200 Today.
At Breit Cantor Grana Buckner, we help people who have been harmed through the negligent manufacturing practices of pharmaceutical companies. We have handled many cases involving harmful medications, and we may be able to help you pursue just compensation for any damages you may have experienced by taking valsartan.
If you are using any of the previously mentioned valsartan-containing medications, you may have reason to worry. Please consult your doctor and seek legal representation as soon as possible if you begin to see signs of NDEA exposure.